Chronic hepatitis C
Conditions
Interventions
None listed
Sponsors
Department of Gastroenterology and Hepatology, Okayama University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who are indicated and eligible for interferon alpha treatment; a positive test for anti-HCV antibody and HCV RNA assessed by a quantitative assay, and entry neutrophil counts, platelet counts, and hemoglobin levels of at or above 1,500/microL, 100,000/microL, and 12 g/dL, respectively.
Exclusion criteria
Exclusion criteria: Patients with the followings: other viral infections such as infection with the hepatitis B virus or human immunodeficiency virus; any other cause of liver disease, e.g., autoimmune hepatitis, primary biliary cirrhosis, drug-induced liver disease, and excessive daily intake of alcohol (>40 g per day over the period of more than 5 years); relevant disorders, including decompensated liver disease, cirrhosis, hepatocellular carcinoma, and other malignant neoplastic diseases; concomitant use of immunosuppressive or herbal medications (e.g. Sho-saiko-to); current use of intravenous drugs; poorly controlled diabetes mellitus, hypertension, cardiovascular disease, chronic renal failure, or creatinine clearance values <50 mL/min.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Positive rate of anti-islet autoantibodies. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in glucose tolerance. | — |
Countries
Japan
Contacts
Public ContactYoshiaki Iwasaki
Okayama University Hospital Department of Gastroenterology and Hepatology
Outcome results
None listed